These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 15752685)

  • 1. Rapidly progressive lung disease in a patient with cystic fibrosis on long-term azithromycin: possible role of mycoplasma infection.
    Janahi IA; Abdulwahab A; Elshafie Sittana S; Bush A
    J Cyst Fibros; 2005 Mar; 4(1):71-3. PubMed ID: 15752685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
    Hansen CR; Pressler T; Koch C; Høiby N
    J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics.
    Pirzada OM; McGaw J; Taylor CJ; Everard ML
    J Cyst Fibros; 2003 Jun; 2(2):69-71. PubMed ID: 15463852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
    Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
    Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The clinical characteristics, treatment and outcome of macrolide-resistant Mycoplasma pneumoniae pneumonia in children].
    Bao F; Qu JX; Liu ZJ; Qin XG; Cao B
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Oct; 36(10):756-61. PubMed ID: 24433804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis.
    Phaff SJ; Tiddens HA; Verbrugh HA; Ott A
    J Antimicrob Chemother; 2006 Apr; 57(4):741-6. PubMed ID: 16469851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycoplasma pneumoniae: the other masquerader.
    Liu EM; Janigian RH
    JAMA Ophthalmol; 2013 Feb; 131(2):251-3. PubMed ID: 23411898
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
    Hansen CR; Pressler T; Hoiby N; Johansen HK
    J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilateral acute anterior uveitis as a presenting symptom of Mycoplasma pneumoniae infection.
    Weinstein O; Shneck M; Levy J; Lifshitz T
    Can J Ophthalmol; 2006 Oct; 41(5):594-5. PubMed ID: 17016530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrolide use shortens fever duration in Mycoplasma pneumoniae infection in children: a 2-year experience.
    Lu YJ; Chen TH; Lin LH; Shen CM; Huang CH
    J Microbiol Immunol Infect; 2008 Aug; 41(4):307-10. PubMed ID: 18787737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrolides in cystic fibrosis.
    McArdle JR; Talwalkar JS
    Clin Chest Med; 2007 Jun; 28(2):347-60. PubMed ID: 17467553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF).
    Tazumi A; Maeda Y; Goldsmith CE; Coulter WA; Mason C; Millar BC; McCalmont M; Rendall J; Elborn JS; Matsuda M; Moore JE
    J Antimicrob Chemother; 2009 Sep; 64(3):501-6. PubMed ID: 19584106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.
    Ríos AM; Fonseca-Aten M; Mejías A; Chávez-Bueno S; Katz K; Gómez AM; McCracken GH; Ramilo O; Hardy RD
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3970-3. PubMed ID: 16127085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of macrolide-resistant Mycoplasma pneumoniae infection.
    Saegeman V; Proesmans M; Dumke R
    Pediatr Infect Dis J; 2012 Nov; 31(11):1210-1. PubMed ID: 22668803
    [No Abstract]   [Full Text] [Related]  

  • 15. Azithromycin prophylaxis during a hospital outbreak of Mycoplasma pneumoniae pneumonia.
    Hyde TB; Gilbert M; Schwartz SB; Zell ER; Watt JP; Thacker WL; Talkington DF; Besser RE
    J Infect Dis; 2001 Mar; 183(6):907-12. PubMed ID: 11237807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis.
    Wilms EB; Touw DJ; Heijerman HG
    Ther Drug Monit; 2006 Apr; 28(2):219-25. PubMed ID: 16628134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azithromycin for improving pulmonary function in cystic fibrosis.
    Carr RR; Nahata MC
    Ann Pharmacother; 2004 Sep; 38(9):1520-4. PubMed ID: 15213312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serologic early diagnosis of pneumonia caused by Mycoplasma pneumoniae].
    Schmidt-Ioanas M; Bender M; Roth A; Allewelt M; de Roux A; Lode H
    Dtsch Med Wochenschr; 2006 Mar; 131(12):613-7. PubMed ID: 16544236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycoplasma pneumoniae-associated mucositis with severe blistering stomatitis and pneumonia successfully treated with azithromycin and infusion therapy.
    Demitsu T; Kawase M; Nagashima K; Takazawa M; Yamada T; Kakurai M; Umemoto N; Jinbu Y
    J Dermatol; 2019 Jan; 46(1):e38-e39. PubMed ID: 29952018
    [No Abstract]   [Full Text] [Related]  

  • 20. Exploring the mechanisms of macrolides in cystic fibrosis.
    Equi AC; Davies JC; Painter H; Hyde S; Bush A; Geddes DM; Alton EW
    Respir Med; 2006 Apr; 100(4):687-97. PubMed ID: 16185859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.